Evolus (NASDAQ:EOLS) Stock Price Down 2.4% – Time to Sell?

Evolus, Inc. (NASDAQ:EOLS)’s share price dropped 2.4% during trading on Monday . The stock traded as low as $12.80 and last traded at $12.72. Approximately 41,269 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 590,097 shares. The stock had previously closed at $13.03.

Analysts Set New Price Targets

A number of research firms have weighed in on EOLS. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Wednesday, March 5th. Barclays upped their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, March 5th.

Evolus Stock Performance

The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market cap of $790.39 million, a price-to-earnings ratio of -13.66 and a beta of 1.28. The stock’s 50 day moving average is $13.55 and its two-hundred day moving average is $13.84.

Insiders Place Their Bets

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now directly owns 32,183 shares of the company’s stock, valued at $418,057.17. This trade represents a 28.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rui Avelar sold 27,904 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares in the company, valued at $4,806,312.42. This represents a 7.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,324 shares of company stock valued at $716,856. 6.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Evolus

Institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV purchased a new position in Evolus in the 4th quarter valued at about $49,000. IFP Advisors Inc lifted its position in Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after buying an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Evolus in the fourth quarter valued at about $106,000. Rafferty Asset Management LLC purchased a new position in Evolus in the 4th quarter worth approximately $115,000. Finally, Quantbot Technologies LP acquired a new stake in Evolus during the 4th quarter valued at $118,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.